Page 337 - Read Online

Page 14 of 17 Shrestha et al. Hepatoma Res 2019;5:32 I http://dx.doi.org/10.20517/2394-5079.2019.24

sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
14. Kudo M. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers 2018;10:412.
15. Zhu AX, Kang Y-K, Yen C-J, Finn RS, Galle PR, et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study
of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated
baseline alpha-fetoprotein (AFP) following first-line sorafenib. J Clin Oncol 2018;36:4003.
16. Floudas CS, Brar G, Greten TF. Immunotherapy: Current Status and Future Perspectives. Dig Dis Sci 2019;64:1030-40.
17. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive,
advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-50.
18. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic
melanoma. N Engl J Med 2010;363:711-23.
19. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell
2015;27:450-61.
20. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
21. Siu EH, Chan AW, Chong CC, Chan SL, Lo KW, et al. Treatment of advanced hepatocellular carcinoma: immunotherapy from
checkpoint blockade to potential of cellular treatment. Transl Gastroenterol Hepatol 2018;3:89.
22. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
23. Hato T, Goyal L, Greten TF, Duda DG, Zhu AX. Immune checkpoint blockade in hepatocellular carcinoma: current progress and
future directions. Hepatology 2014;60:1776-82.
24. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
25. Shrestha R, Prithviraj P, Anaka M, Bridle KR, Crawford DHG, et al. Monitoring Immune Checkpoint Regulators as Predictive
Biomarkers in Hepatocellular Carcinoma. Front Oncol 2018;8:269.
26. Webb ES, Liu P, Baleeiro R, Lemoine NR, Yuan M, et al. Immune checkpoint inhibitors in cancer therapy. J Biomed Res 2018;32:317-26.
27. Ardolino L, Joshua A. Immune checkpoint inhibitors in malignancy. Aust Prescr 2019;42:62-7.
28. Okusaka T, Ikeda M. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. ESMO Open
2018;3:e000455.
29. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities.
Oncoimmunology 2012;1:48-55.
30. Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, et al. Regulation of accumulation and function of myeloid derived suppressor
cells in different murine models of hepatocellular carcinoma. J Hepatol 2013;59:1007-13.
31. Jenne CN, Kubes P. Immune surveillance by the liver. Nat Immunol 2013;14:996-1006.
32. Okrah K, Tarighat S, Liu B, Koeppen H, Wagle MC, et al. Transcriptomic analysis of hepatocellular carcinoma reveals molecular
features of disease progression and tumor immune biology. NPJ Precis Oncol 2018;2:25.
33. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006;313:1972-5.
34. Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, et al. Comparative analysis of various tumor-associated antigen-specific
t-cell responses in patients with hepatocellular carcinoma. Hepatology 2011;53:1206-16.
35. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab
in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
36. Brar G, Greten TF, Brown ZJ. Current frontline approaches in the management of hepatocellular carcinoma: the evolving role of
immunotherapy. Therap Adv Gastroenterol 2018;11:1756284818808086.
37. Iñarrairaegui M, Melero I, Sangro B. Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. Clin Cancer Res 2018;24:1518-24.
38. Liu X, Qin S. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist 2019;24:S3-S10.
39. Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouattour M, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs
best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2019;37:4004.
40. Busato D, Mossenta M, Baboci L, Di Cintio F, Toffoli G, et al. Novel immunotherapeutic approaches for hepatocellular carcinoma
treatment. Expert Rev Clin Pharmacol 2019;12:453-70.
41. Qin S, Finn RS, Kudo M, Meyer T, Vogel A, et al. A phase 3, randomized, open-label, multicenter study to compare the efficacy
and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular
carcinoma. J Clin Oncol 2018;36:TPS3110.
42. Huang J, Mo H, Wu D, Chen X, Ma L, et al. Phase I study of the anti-PD-1 antibody SHR-1210 in patients with advanced solid tumors.
J Clin Oncol 2017;35:e15572.
43. Xu J, Zhang Y, Jia R, Yue C, Chang L, et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular
Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clin Cancer Res
2019;25:515-23.
44. Qin SK, Ren ZG, Meng ZQ, Chen ZD, Chai XL, et al. LBA27A randomized multicentered phase II study to evaluate SHR-1210 (PD-1
antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment. Ann Oncol
2018;29:mdy424.029.
45. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1
costimulatory molecule to inhibit T cell responses. Immunity 2007;27:111-22.